Detalhe da pesquisa
1.
Targeting MYC effector functions in pancreatic cancer by inhibiting the ATPase RUVBL1/2.
Gut
; 2024 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821858
2.
Combinatorial Expression of NK Cell Receptors Governs Cell Subset Reactivity and Effector Functions but Not Tumor Specificity.
J Immunol
; 208(7): 1802-1812, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288470
3.
Cutting Edge: mTORC1 Inhibition in Metastatic Breast Cancer Patients Negatively Affects Peripheral NK Cell Maturation and Number.
J Immunol
; 206(10): 2265-2270, 2021 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33931486
4.
Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
Eur J Immunol
; 45(5): 1560-9, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25726929
5.
Isolation and Identification of Dendritic Cell Subsets from Human and Mouse Tumors.
Methods Mol Biol
; 2618: 187-197, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36905518
6.
IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Breast Cancer Res Treat
; 136(3): 659-71, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23065032
7.
Peripheral natural killer cells in chronic hepatitis B patients display multiple molecular features of T cell exhaustion.
Elife
; 102021 01 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507150
8.
Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.
Front Immunol
; 7: 413, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27777574
9.
Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients.
Innate Immun
; 19(1): 76-85, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22781631